FDA approves AstraZeneca treatment for cases reacting badly to vaccines

By Akshay Kedari  Date: 2021-12-09

FDA approves AstraZeneca treatment for cases reacting badly to vaccines

The U.S. FDA has reportedly issued an emergency use authorization of synthetic AstraZeneca antibodies for the prevention of Covid-19 infections in people who have had a severe reaction to vaccines. This is the first time the U.S. health authority has granted emergency approval for such a purely preventative treatment.

According to the FDA, the drug Evusheld isn’t a replacement for vaccination in those for whom COVID-19 vaccination is advised and can only be used by patients with a weaker immune system or who are unable to be vaccinated due to medical reasons such as a severe allergic reaction. In such cases, the drug can be provided for people who are aged 12 or above.

For those unaware, Evusheld is a drug that combines two synthetic antibodies (tixagevimab and cilgavimab) and is administered as two consecutive intramuscular injections. These antibodies aid the immune system in combating the virus by attacking the virus's spike protein, which permits it to access and infect cells. 

As per a statement given by the FDA, it may be useful for pre-exposure protection for six months and cannot be given to someone who is already infected with the virus, though AstraZeneca is testing it for this purpose.

The drug is known to have possible side effects like allergic reactions, bleeding from the injection site, headaches, and lethargy.

The FDA's approval was based on a clinical trial that included unvaccinated adults over the age of 59, suffering from chronic diseases, or those who were at high risk of infection. The result showed that the therapy reduced the probability of developing COVID-19 by 77%.

In the United States, two antibody cocktails developed by Regeneron and Eli Lilly are presently approved for the prevention of infection, but only in those who have recently been exposed to the virus or who have a high risk of being exposed to the disease.

Source Credit:

https://www.ndtv.com/world-news/us-authorizes-astrazeneca-evusheld-drug-for-covid-treatment-in-some-cases-2643322

About Author

Akshay Kedari     aeresearch.net

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Tesla gets German nod to develop test cars at unfinished Berlin factory

Tesla gets German nod to develop test cars at unfinished Berlin factory

By Akshay Kedari

Tesla Inc. has reportedly received authorization to produce test cars at its unfinished German gigafactory. This approval comes as the EV maker continues to wait for the project's final permission, although Tesla will not be permitted to sell the...

Power Gummies secures USD 6 million in 9Unicorns-led Series A funding

Power Gummies secures USD 6 million in 9Unicorns-led Series A funding

By Akshay Kedari

Nutraceutical startup Power Gummies has reportedly raised USD 6 million during a Series A funding which was led by 9Unicorns. The round also saw participation from other investors such as NB Ventures, Sharpp Ventures (Marico Family Office), Wipr...

Marriot establishes a research & development lab to promote innovation

Marriot establishes a research & development lab to promote innovation

By Akshay Kedari

Hospitality behemoth Marriott International Inc. has reportedly established a research and development lab called the “Design Lab” to strengthen and optimize the rollout of its current product offerings. This lab will encompass all areas...

Sony to steer into the electric vehicle space with a new mobility unit

Sony to steer into the electric vehicle space with a new mobility unit

By Akshay Kedari

Sony will establish a subsidiary, ‘Sony Mobility Inc.’ that will primarily focus on its EV business. The company unveiled a new electric SUV prototype, called the Vision-S 02 at CES 2022. Sony Group Corporation, a Japanese electroni...

Apple becomes world's first company to reach USD 3 trillion valuation

Apple becomes world's first company to reach USD 3 trillion valuation

By Akshay Kedari

Apple Inc. recently became the first company to have a stock market value of USD 3 trillion, boosted by investor confidence that the iPhone manufacturer will continue to release best-selling products while foraying into new markets such as self-drivi...